摘要
目的探讨利可君对恶性肿瘤盆腔放疗所致骨髓抑制的临床疗效。方法选取2017年1月1日~2020年12月20日在南方医科大学附属南海医院收治的盆腔肿瘤术后放疗的患者96例,随机分为观察组及对照组,每组48例,对照组予以调强适形放疗,观察组则在放疗前1周开始服用大剂量利可君预防性治疗,比较两组治疗完成情况、骨髓抑制情况、白细胞及血小板变化情况及不良反应发生情况。结果两组放疗完成率均为100.00%;观察组骨髓抑制总发生率低于对照组,差异有统计学意义(P<0.05);放疗后两组白细胞与血小板计数均下降,且对照组低于观察组,差异有统计学意义(P<0.05);两组均未见恶心呕吐,腹泻腹痛等利可君药物相关的不良反应,肝肾功能均正常。结论盆腔调强适形放疗所致骨髓抑制反应发生率较高,大剂量利可君在防治盆腔恶性肿瘤患者调强适形放疗所致骨髓抑制方面具有较好的效果,且无明显不良反应,安全可靠。
Objective To investigate the clinical effect of Leucogen on bone marrow suppression caused by pelvic radiotherapy of malignant tumors.Methods A total of 96 patients undergoing postoperative radiotherapy for pelvic tumors who were admitted to Nanhai Hospital of Southern Medical University from January 1,2017 to December 20,2020 were randomly divided into observation group and control group,with 48 cases in each group.The control group received intensity-modulated conformal radiotherapy,while the observation group began to take prophylactic treatment with high-dose Leucogen 1 week before radiotherapy.The completion of treatment,bone marrow suppression,white blood cell and platelet changes and adverse reactions were compared between the two groups.Results The completion rate of radiotherapy in both groups was 100.00%;the total incidence of bone marrow suppression in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05);After radiotherapy,the white blood cell and platelet counts of the two groups decreased,and the control group was lower than the observation group,the difference was statistically significant(P<0.05);There were no adverse reactions related to Leucogen such as nausea,vomiting,diarrhea,abdominal pain,etc.,and liver and kidney functions were normal.Conclusion The incidence of bone marrow suppression caused by pelvic intensity-modulated conformal radiotherapy is higher.High-dose Leucogen has a good effect in the prevention and treatment of bone marrow suppression caused by intensity modulated radiotherapy in patients with pelvic malignant tumors,and it has no obvious adverse reactions and is safe and reliable.
作者
张永胜
唐武兵
ZHANG Yong-sheng;TANG Wu-bing(Clinical Oncology Center,the University of Hong Kong-Shenzhen Hospital,Shenzhen 518000,Guangdong,China;Department of Oncology,Nanhai Hospital,Southern Medical University,Foshan 528200,Guangdong,China;The Second Clinical School of Southern Medical University,Guangzhou 510000,Guangdong,China)
出处
《医学信息》
2021年第16期131-133,共3页
Journal of Medical Information
基金
佛山市科技创新项目(编号:2016AG100492)
佛山市“十三五”重点专科建设项目(编号:FSZDZK135042)。
关键词
利可君
盆腔恶性肿瘤
调强适形放疗
骨髓抑制
Leucogen
Pelvic malignant tumor
Intensity-modulated conformal radiotherapy
Bone marrow suppression
